Dr. Maria Millan has been recognized by the San Francisco Business Times as one of the most influential women in Bay Area business for her work leading the California Institute for Regenerative Medicine (CIRM), California’s stem cell and regenerative medicine agency. Under her leadership, CIRM has generated a robust and growing portfolio as a patient-centric funder, … Continue reading CIRM President & CEO Dr. Maria Millan recognized as one of the most influential women in Bay Area business
Maria T. Millan
Funding a Clinical Trial for a Functional Cure for HIV
The use of antiretroviral drugs has turned HIV/AIDS from a fatal disease to one that can, in many cases in the US, be controlled. But these drugs are not a cure. That's why the governing Board of the California Institute for Regenerative Medicine (CIRM) voted to approve investing $6.85 million in a therapy that aims … Continue reading Funding a Clinical Trial for a Functional Cure for HIV
Chance discovery could lead to a treatment for skin ulcers
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Dr. Antoni Ribas in his research lab on the UCLA Campus: Photo courtesy Ann Johansson When UCLA's Dr. Antoni Ribas was researching a potential therapy for melanoma, a form of skin cancer, he stumbled upon something unexpected. That unexpected discovery has now resulted in him getting … Continue reading Chance discovery could lead to a treatment for skin ulcers
Stem Cell Agency Board Approves Roadmap for Next Five Years
Dr. Maria Millan, CIRM's President & CEO It's hard to get somewhere if you don't know where you are going. Without a map you can't plan a route to your destination. That's why the CIRM Board approved a new Strategic Plan laying out a roadmap for the Stem Cell Agency for the next five years. … Continue reading Stem Cell Agency Board Approves Roadmap for Next Five Years
Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Dr. Ezra Cohen, photo courtesy UCSD Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, … Continue reading Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers
Board Funds Fifteen Bridges to Stem Cell Research and Therapy Programs Across California and New Sickle Cell Disease Trial
Yesterday the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $8.39 million to the University of California, San Francisco (UCSF) to fund a clinical trial for sickle cell disease (SCD). An additional $51.08 million was awarded to fifteen community colleges and universities across California to fund undergraduate and master’s level programs that … Continue reading Board Funds Fifteen Bridges to Stem Cell Research and Therapy Programs Across California and New Sickle Cell Disease Trial
CIRM Board Approves New Clinical Trial for ALS
This past Friday the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $11.99 million to Cedars-Sinai to fund a clinical trial for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a neurodegenerative disease that results in the death of nerve cells in the brain and spinal cord, causing … Continue reading CIRM Board Approves New Clinical Trial for ALS
CIRM Funded Trial for Parkinson’s Treats First Patient
Dr. Krystof Bankiewicz Brain Neurotherapy Bio, Inc. (BNB) is pleased to announce the treatment of the first patient in its Parkinson’s gene therapy study. The CIRM-funded study, led by Dr. Krystof Bankiewicz, is one of the 64 clinical trials funded by the California state agency to date. Parkinson’s is a neurodegenerative movement disorder that affects … Continue reading CIRM Funded Trial for Parkinson’s Treats First Patient
CIRM Board Approves Third Clinical Trial for COVID-19
Dr. Xiaokui Zhang (left), Dr. Albert Wong (center), and Dr. Preet Chaudhary (right) Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $750,000 to Dr. Xiaokui Zhang at Celularity to conduct a clinical trial for the treatment of COVID-19. This brings the total number of CIRM clinical trials to 64, including … Continue reading CIRM Board Approves Third Clinical Trial for COVID-19
Stem Cell Agency Board Approves Three More Projects Targeting COVID-19
Dr. Jianhua Yu (left), Dr. Helen Blau (center), and Dr. Albert Wong (right) The COVID-19 virus targets many different parts of the body, often with deadly or life-threatening consequences. This past Friday the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investments in three early-stage research programs taking different approaches to battling … Continue reading Stem Cell Agency Board Approves Three More Projects Targeting COVID-19
The Stem Cellar 